Journal of B.U.ON.: official journal of the Balkan Union of Oncology (J BUON )

Publisher: Balkan Union of Oncology

Description

  • Impact factor
    0.76
    Show impact factor history
     
    Impact factor
  • 5-year impact
    0.65
  • Cited half-life
    3.30
  • Immediacy index
    0.09
  • Eigenfactor
    0.00
  • Article influence
    0.13
  • Other titles
    Journal of BUON, Journal of Balkan Union of Oncology
  • ISSN
    1107-0625
  • OCLC
    42889499
  • Material type
    Periodical
  • Document type
    Journal / Magazine / Newspaper

Publications in this journal

  • Arzu Didem Yalcin, Gizem Esra Genc, Betl Celik, Saadet Gumuslu
    Journal of B.U.ON.: official journal of the Balkan Union of Oncology 09/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: In this study, the antiproliferative and apoptotic effects of sunitinib (SU-11248, Sutent) which is used for targeted therapy was evaluated on HeLa cell line originated from human cervix carcinoma. Methods: Three different doses of sutent (D1= 1 μM, D2= 5 μM, D3= 10 μM) were administered to cells for 72 h to determine the optimal dose. Results: Increase in apoptotic index (AI), decrease in mitotic index (MI) of cells and slow down in proliferation rate were achieved at the dose level of 10 μM, especially at 72 h. All these findings were statistically significant (p<0.001). In addition, anaphase bridges and existence of tripolar metaphase cells that were observed at 72 h were possibly attributable to a chromosomal instability arising from shortening of telomere. Conclusion: In this study, sutent effected cell kinetic parameters significantly. These results are consistent with other studies in the literature. In addition, anaphase bridges which were seen in mitosis preparations were interpreted as shortening or degradation of the telomere.
    Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 18(1):253-60.
  • [Show abstract] [Hide abstract]
    ABSTRACT: We present our experience on 6 patients (4 females, 2 males) with elastofibroma dorsi. The diagnosis was based on imaging studies along with clinical examination. Surgery was decided due to the symptomatic nature of the tumors along with the consent and willingness of the patients. All patients had an uncomplicated course and long term follow up did not show any disease recurrence.
    Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):573-6.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Many studies have pointed out a possible role of ghrelin, in the pathogenesis and natural history of gastrointestinal tract malignancies. The objective of this study was to estimate serum total ghrelin levels (STGL) in patients with colon cancer (CC) and to evaluate the value of this assay in research and clinical practice. Methods: STGL were measured pre-operatively in 95 CC patients and in 39 healthy controls, and were correlated with patients' age, gender, body mass index (BMI), tumor location, Dukes stage, grade of differentiation and patients' survival. Results: STGL were significantly elevated in patients with CC (127.6±34.5 pmol/L) vs healthy controls (89.3±19 pmol/L, p<0.05). STGL were significantly higher in endstage (180±10 pmol/L) vs initial-stage CC (94.2±22.6 pmol/L; p<0.05). Furthermore, patients with poorly differentiated tumors had statistically significantly higher STGL (144.5±30.7 pmol/L) compared to those with well (91.8±23.6 pmol/L) or moderately well (126±34 pmol/L) differentiated CC cases (p<0.05). No statistically significant differences in the patients' STGL were noticed with respect to their demographic/ clinical characteristics, tumor location and survival (p>0.05). Conclusions: The obtained results showed a link between elevated STGL and CC, suggesting that colon tumors contribute to ghrelin's production.
    Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):388-93.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To investigate both the clinicopathological and immunohistochemical characteristics of a very rare skin cancer - Merkel cell carcinoma (MCC) - and to review the relevant literature. Methods: The study group was composed of 12 patients, with mean age 53.08±10.26 years. Multiple subcutaneous masses and lymph node metastases were surgically removed. Paraffin blocks of formaldehyde-fixed tumor tissue were cut and stained for histological, histochemical and immunohistochemical studies. The following antibodies (Dacopatt) were used: Chromogranin A, CK20, CK7, Melan A, CD20 and CD45Ro. Results: The tumors involved the dermis while sparing the epidermis. The most frequently affected sites were sun-exposed skin (8 patients on the head and neck) and the most common histological subtype of MCC was the intermediate variant. Six patients had lymph node metastasis and 2 had locoregional recurrences. Haematogenous lung metastases of MCC and primary located in the trunk were found only in our youngest patient (36-year-old). Immunostaining revealed positive reactivity for neuroendocrine and epithelial markers and negative reactivity for melanoma, B/T lymphomas and small cell metastatic lung carcinoma. Conclusion: MCC is a rare malignant primary cutaneous neoplasm with epithelial and neuroendocrine differentiation, demanding wide local excision. The pathological differential diagnosis includes basal cell carcinoma, melanoma, lymphoma, and metastatic small cell lung carcinoma. The diagnosis of MCC is possible only immunohistochemically, by using the wide spectrum of antibodies, characteristic of microscopically similar tumors.
    Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):530-4.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: The purpose of this retrospective study was to analyse incidence trends for thyroid cancer (TC) treated at the Ion Chiricuta Institute of Oncology (IOCN), Romania. Methods: Between 1970 and 2009, 2838 patients at our institute were diagnosed with TC, treated and followed up. We analysed epidemiological data, distribution by age groups,sex, histopathological diagnosis, treatments and 5- and 10-year overall survival rates. Results: TC increased 10-fold in the last decade. Patients' mean age ± standard deviation (SD) was 45.6 (±27.8) years. Although women represented 88.8% and men 11.2% of these patients, men's 5-year overall survival rate (89.7%) was lower - but not significantly - than that of women's (97.9%) (p=0.435). Patients aged 46 years and older had the lowest 5- and 10-year overall survival rates (94.9 and 87.8%, respectively). Conclusion: Aggressive histology, older age and male gender significantly influenced survival rates. The high incidence of TC underlines the necessity of having a national/ regional TC registry to improve our epidemiological data.
    Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):524-9.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To investigate whether celastrol could show synergism combined with lapatinib in HepG2 human hepatocellular carcinoma (HCC) cell line in vitro. Methods: The effects of treatment with lapatinib and/or celastrol on cell growth were determined using MTT assay. Drug synergy was determined using combination index (CI) methods derived from Chou-Talalay equations using CalcuSyn software. Apoptotic morphology was observed by fluorescence microscope with Hoechst 33258 staining. The expression of EGFR of cell surface was performed by flow cytometry. Changes of apoptotic and growth pathways-related proteins were analysed by Western blotting. Results: The combination of celastrol and lapatinib produced strong synergy in growth inhibition and apoptosis in vitro in comparison to single-agent treatments. Moreover, celastrol enhanced the ability of lapatinib to down regulate EGFR protein expression in HepG2 cells. Conclusion: These data indicate that the combination of celastrol and lapatinib could be used as a novel combination regimen which could hopefully provide strong anticancer synergy in the treatment of HCC.
    Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):412-8.
  • Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):581-2.
  • Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):582-3.
  • [Show abstract] [Hide abstract]
    ABSTRACT: According to recent epidemiological studies, malignant diseases represent the second cause of mortality worldwide and metastasis is the main cause of morbidity and mortality in most cancers. Even if the concept of "cancer stem cells" (CSCs) was anticipated by the genius of Rudolph Virchow, the father of modern pathology, more than 150 years ago, it is only in last few years that that scientists have begun to develop strategies aimed at inhibiting CSCs at a molecular level, the only way cancer can truly be attacked, by crossing the border between histology and molecular biology. The current concise review aims at emphasizing the main characteristics of tumor initiating cells, bridging the basic science to clinical hematology and oncology.
    Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):328-335.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To explore the values of sequential (18)F-FDG PET/CT scanning in patients with non-surgical esophageal squamous cell carcinoma (ESCC) who received concurrent chemoradiotherapy (CCRT). Methods: Twenty-eight patients with pathologically confirmed stage I-IV ESCC and who received definitive CCRT were prospectively enrolled into this trial. The (18)F-FDG PET/CT scans were performed four times. The maximum standardized uptake values (SUVmax) of each scanning were named as SUVmaxpet1, SUVmaxpet2, SUVmaxpet3, and SUVmaxpet4, respectively. The tumor volume with SUV greater than 40% of SUVmax was named as metabolic tumor volume (MTV). Follow-up investigation of patients was performed to record progression-free survival (PFS), relapse-free survival (RFS), and overall survival time (OS). Results: The average value of MTV before treatment is 19.3 ml. The average value of SUVmax at four time points was 13.0 ± 7.4, 6.4 ± 3.2, 4.7 ± 1.9, and 3.4 ±1.8, respectively. Median follow-up time was 18.5 months (range 5-40). There was statistically significant difference in ΔR14 ((SUVmaxpet1- SUVmaxpet4) / SUVmaxpet1). Multivariate Cox regression survival analysis indicated that the MTV was an independent prognostic factor for PFS and RFS (HR = 1.13 and 1.14, respectively) before treatment. Conclusion: In CCRT of non-surgical ESCC, MTV before treatment could independently predict OS survival. SUVmaxpet2, SUVmaxpet3, and SUVmaxpet4 could predict RFS. Patients with reductions of SUVmaxpet4 less than 75% had a poor PFS, RFS, and OS.
    Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):517-23.
  • Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):577-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Cigarette smoking was regarded as the most important carcinogenic factor of lung cancer, yet in recent years lung cancer in never-smokers is an increasingly prominent public health issue. The aim of this study was to assess the epidemiological and clinicopathological characteristics of never-smoker patients with non small cell lung cancer (NSCLC), focusing on clinical risk factors and survival. Methods: We retrospectively analyzed 290 NSCLC patients who presented between 2006 and 2011. Differences in clinical features and survival between never- and ever- smoker patients were analyzed. Student's t-test and Mann-Whitney U-test were used to assess the significance of the variables between the groups. Survival curves were calculated using Kaplan-Meier method. Hazard ratio (HR) for death and its 95% confidence interval (CI) were calculated by Cox regression analysis. Results: There were 243 (83.8%) ever-smokers and 47 (16.2%) never-smokers. In never-smokers females predominated (80.9%) as well as patients with adenocarcinomas (78.7%). At the time of analysis 143 (49.3%) patients had died. The 5-year overall survival (OS) rates were not significantly different between never- and ever-smokers (p=0.410) . The median OS of all patients was 26 months (95% CI: 16.8-35.2). The median OS was 23 months (95% CI: 11.8- 34.2) for never-smokers and 30 months ∥95% CI: 19.7-40.3) for ever-smokers (p=0.410). Never-smokers tended to present with more advanced disease than ever-smokers (p<0.004) and also with more advanced age (p<0.001). The HR for death increased with poorer Eastern Cooperative Oncology Group ( ECOG ) performance status (PS) (ECOG 2=3), advanced stage (stage 3=4) and untreated patients. Slightly lower risk for death was registered in patients with adenocarcinoma vs those with squamous cell carcinoma (SCC). Conclusion: Although no difference in survival was seen, definite epidemiologic differences do exist between never- smokers and ever-smokers patients with NSCLC. Future efforts should focus on the underlying biological differences, and on identifying potential non-tobacco related risk factors in order to improve treatment strategies for these two groups of NSCLC patients.
    Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):453-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: This study aimed to investigate the expression of p53 and Ki67 genes in renal cell carcinoma (RCC) and its possible clinical value. Methods: A retrospective analysis of clinical data from 1239 patients with RCC was performed to explore the relationship between the expression of Ki67 and p53 proteins and tumor stage, grade and prognosis. Results: p53 expression was not significantly correlated with TNM stage and Fuhrman grade (p>0.05); Ki67 expression was significantly correlated with TNM stage and Fuhrman grade (p<0.05). Kaplan-Meier and log-rank survival rate results showed that the prognosis of Ki67 and p53 double-positive group was significantly inferior to the single-positive and negative group (p<0.001). In the multivariate Cox risk regression analysis model, TNM stage, relative risk/RR=3.196, p<0.001), Fuhrman grade (RR=3.196, p<0.001) and Ki67 and p53 double-positive [Ki67 (+) p53 (+) , RR=3.196, p<0.001] were significantly correlated with tumor prognosis, and independent predictors of the patient disease-free survival (DFS). Conclusion: The combined detection of p53 and Ki67 expressions, which are superior to single marker, could be used to improve significantly the accuracy of prognosis of RCC patients.
    Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):512-6.
  • Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):580.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Primary neuroendocrine carcinoma of the breast (NECB) is a rare distinct type of breast carcinoma. There are only some case reports on this topic published in the past. There is still little known on the optimal treatment outcomes, while a wide variety of treatments is proposed by several authors. In this study we searched the literature on NECB in PubMed to clarify its prognosis and possible optimal therapeutic strategies. Methods: Eighty-six cases of primary NEC, included our case, were collected from PubMed between 1980 and 2013. Initial stage, estrogen receptor (ER)/progesterone receptor (PR)/ human epidermal growth factor receptor 2 (HER-2), surgical procedures, adjuvant treatment and overall survive (OS) were analyzed using the Statistical Package for the Social Sciences ( SPSS, v 16.0 ). Results: All 86 patients enrolled were eligible. Their mean age at diagnosis was 53.9 years (range 25-83) and 1 case was in a male. Overall survival (OS) at 48 months was 83.5%. Patients with enlarged tumor size (10 patients with tumor size >5.0 cm) or advanced stage (stage III 15 patients, stage IV 2 patients) had poor OS (48-month OS: 51.4 vs 97.1% with tumors >5cm vs ≤2cm, respectively and 0.0%, 68.1%, 72.9% and 95.8% in stage IV, III, II and I, respectively). Patients with positive ER, PR or HER-2 had significantly better OS than did those without (ER, p<0.001; PR, p<0.001; HER-2, p=0.082). Besides, all 60 patients with initial primary surgery and without lymph node dissection (LND) showed better OS than those with initial primary surgery without LND, the difference however being not significant (p=0.133). Conclusion: Definite diagnosis and clinical stage are prerequisites in the initial approach in NECB. When detected early the disease may have a good prognosis with combined modality treatment such as chemotherapy, surgery, and radiation therapy. An appropriate therapeutic strategy for this group is also important. Our analysis showed that for patients with early localized disease only primary surgery is recommended and LND is optional. In patients with positive steroid receptors postoperative hormonotherapy is suggested.
    Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):419-29.
  • Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):584.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Non-functioning pancreatic endocrine tumors (NF-PETs) comprise the majority of pancreatic endocrine tumors. We present our experience from the management of 18 patients with NF-PET. Methods: From May 2002 to June 2013, 18 patients were admitted in our hospital for the management of NF-PETs. We analyzed their clinical presentation, preoperative evaluation, surgical and postoperative management and the outcome. Results: The tumor was located in the pancreatic head in 13 (72%) patients and in the body and tail of the pancreas in the remaining 5 (28%). Four patients (22%) had stage IIIa, 7 (39%) stage IIIb and 7 (39%) stage IV. Twelve (67%) patients with pancreatic head tumor underwent pancreatoduodenectomy (PD). In one case (5%), the tumor was deemed unresectable and the remaining 5 (28%) patients underwent distal pancreatectomy and splenectomy (DPSP). Four (22%) patients with unilobar metastatic liver disease underwent hemihepatectomy or segmentectomy. Perioperative mortality was 0%. Postoperatively, all stage IV patients received peptide receptor radionuclide treatment (PRRT). The 5-year overall survival rate was 61%, with a median survival of 71 months, whereas the 5-year overall survival rate after diagnosis of hepatic metastases was 45%. Conclusion: Surgical resection is the gold standard for the treatment of NF-PETs. A formal resection appears to be the standard procedure when malignancy is verified or suspected. Aggressive surgery should be undertaken in patients with locally advanced or metastatic NF-PETs, as it may prolong survival. In stage IV patients, intra-arterial PRRT, after super-selective catheterization of the hepatic artery, is a promising therapeutic modality.
    Journal of B.U.ON.: official journal of the Balkan Union of Oncology 04/2014; 19(2):449-52.

Related Journals